Folks,
Here are a few reasons to look into Conexeu Sciences Inc. (CNXU):
1. One formula, five markets: CXU is a single patented formulation aimed at aesthetics, wound care, dental, veterinary, and 3D bioprinting — expansion through staged clearances rather than reformulating a new product for each.
2. A novel "liquid-to-gel" mechanism: It flows as a liquid thin enough to pass through a 30-gauge needle, then gels in place as it reaches body temperature (~37°C) in about 10 minutes — the company's "10-Minute Tissue."
3. Built to conform, not just fill: Once set, CXU shapes to irregular geometries and fills voids without migrating, which the company frames as taking "fit" off the table as a failure point.
4. A clear scientific rationale: The pitch rests on a simple premise — regeneration needs cells, signals, and a scaffold (the ECM), and the scaffold is the one piece the body can't reliably rebuild on its own. CXU is designed to be that scaffold.
5. A different answer to a weight-loss side effect: As rapid weight loss leaves tissue hollowed and lax, Conexeu is aiming at restoration — regenerating lost tissue rather than just filling space the way legacy fillers do.
6. A genuine white-space claim: The company's own landscape review of cleared wound-care devices found none offering a flowable, injectable, thermosensitive ECM like CXU.
Anyways...
That's all for now!
Until Next Time,
-ZT Team
|
No comments:
Post a Comment